World Pharma News

Syndicate content World Pharma News
World Pharma News - one of the world's leading web-based pharmaceutical news publications - is committed to providing and disseminating the most prominent pharmaceutical news and achievements
Updated: 8 hours 18 min ago

Europe's largest initiative launches to accelerate therapy development for COVID-19 and future coronavirus threats

Wed, 08/26/2020 - 10:00
CARE (Corona Accelerated R&D in Europe) a new consortium supported by the Innovative Medicines Initiative (IMI) public-private partnership announced its launch to accelerate the discovery and development of urgently needed medicines to treat SARS-CoV-2, the virus that causes COVID-19. With a grant totaling € 77.7 million, CARE is funded by

73,000 Scientists collaborate over new COVID-19 Data Portal to speed up vaccine development

Wed, 08/26/2020 - 00:00
More than 73,000 users collaborate on new online platform set up by the European Open Science Cloud Initiative, where scientists share COVID-19 data and accelerate our understanding of the virus to help develop treatments and vaccines quicker.

A new website that allows scientists to share difficult-to-find SARS-CoV-2 data from clinical trials, research centres, hospitals and national healthcare systems, has seen thousands of users collaborating to help beat the novel coronavirus.

Phase I clinical trial initiated for monoclonal antibody combination for the prevention and treatment of COVID-19

Tue, 08/25/2020 - 12:00
The first participants have been dosed in a Phase I trial of AZD7442, a combination of two monoclonal antibodies (mAbs) in development for the prevention and treatment of COVID-19.

The trial, called NCT04507256, will evaluate the safety, tolerability and pharmacokinetics of AZD7442.(1) The trial will include up to 48 healthy participants in the UK aged 18 to 55 years and is funded by the

Blocking cellular communication stops SARS-CoV-2

Tue, 08/25/2020 - 10:00
In the transmission of signals within the cell which, for example, stimulate cell growth or trigger metabolic processes, phosphate groups play an important biochemical role. The phosphate groups are often attached to proteins or removed to control activity. In this process, a change in the protein triggers the next one and the signal is transmitted in a signaling cascade. The target is usually the cell nucleus, where genes are switched on or off.

Nasal vaccine against COVID-19 prevents infection in mice

Mon, 08/24/2020 - 12:00
Scientists at Washington University School of Medicine in St. Louis have developed a vaccine that targets the SARS-CoV-2 virus, can be given in one dose via the nose and is effective in preventing infection in mice susceptible to the novel coronavirus. The investigators next plan to test the vaccine in nonhuman primates and humans to see if it is safe and effective in preventing COVID-19 infection.

Bayer and Informed Data Systems Inc. (One Drop) join forces to jointly develop digital health products across therapeutic areas

Mon, 08/24/2020 - 10:00
Bayer and Informed Data Systems Inc. (One Drop), a US-based digital health company, today announced that they have entered into an agreement to jointly develop digital health products for multiple therapeutic areas. The aim of the collaboration is to provide integrated services empowering patients to manage certain conditions.

FDA issues emergency use authorization for convalescent plasma as potential promising COVID-19 treatment

Sun, 08/23/2020 - 23:00
Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for investigational convalescent plasma for the treatment of COVID-19 in hospitalized patients as part of the agency's ongoing efforts to fight COVID-19. Based on scientific evidence available, the FDA concluded, as outlined in its decision memorandum, this product may be effective in treating COVID-19 and that the known and potential benefits of the product outweigh the known and potential risks of the product.

Pfizer and BioNTech share positive early data on lead mRNA vaccine candidate BNT162b2 against COVID-19

Fri, 08/21/2020 - 10:00
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) shared additional Phase 1 safety and immunogenicity data from their ongoing U.S. study of the BNT162 mRNA-based vaccine program against SARS-CoV-2, which has advanced into Phase 2/3 evaluation. The newly released manuscript describes key safety and immunogenicity data from the U.S. Phase 1 trial for the BNT162b2 vaccine candidate,

Roche and Regeneron collaborate to significantly increase global supply of REGN-COV2 investigational antibody combination for COVID-19

Thu, 08/20/2020 - 10:00
Roche (SIX: RO, ROG; OTCQX: RHHBY) and Regeneron (NASDAQ: REGN) announced are joining forces in the fight against COVID-19 to develop, manufacture and distribute REGN-COV2, Regeneron's investigational antiviral antibody combination, to people around the globe. REGN-COV2 could provide a much-needed treatment option for people already experiencing symptoms of COVID-19, and also has the potential to prevent infection in people exposed to the virus, thus slowing the spread of the global pandemic.

Observational study identifies drug that improves survival in sickest COVID-19 patients

Wed, 08/19/2020 - 10:00
Researchers at Hackensack Meridian Health, New Jersey's largest and most comprehensive health network, have utilized its statewide observational database of more than 5,000 hospitalized COVID-19 patients to show that a drug normally used in rheumatoid arthritis and cancer treatments, tocilizumab, improves hospital survival in critically-ill patients admitted to the intensive care unit (ICU).

Sanofi to acquire Principia Biopharma

Tue, 08/18/2020 - 10:00
Sanofi and Principia Biopharma Inc. (NASDAQ: PRNB), a late-stage biopharmaceutical company focused on developing treatments for immune-mediated diseases, entered into a definitive agreement under which Sanofi will acquire all of the outstanding shares of Principia for $100 per share in cash, which represents an aggregate equity value of approximately $3.68 billion (on a fully diluted basis).

Researchers design and test protein that may lead to COVID-19 therapeutic

Mon, 08/17/2020 - 10:00
A novel receptor protein that binds to the SARS-CoV-2 virus and prevents it from entering cells may hold promise for treating COVID-19 and other coronavirus-related diseases, according to research published online Aug. 4 in the journal SCIENCE.

As scientists race to find treatments for COVID-19, many are focused on a specific protein called angiotensin-converting enzyme 2, or ACE2, which is found on various cell surfaces throughout the human body.

AstraZeneca concludes agreement with the European Commission for the supply of up to 400 million doses of AZD1222 COVID-19 vaccine

Fri, 08/14/2020 - 10:00
AstraZeneca has concluded an agreement with the European Commission (EC) to supply up to 400 million doses of the AZD1222 COVID-19 vaccine. Building on the existing agreement with Europe's Inclusive Vaccines Alliance spearheaded by Germany, France, Italy and the Netherlands, this new agreement will give all EU member states the option to access the vaccine in an equitable manner at no profit during the pandemic.

Johnson & Johnson announces agreement with U.S. government for 100 million doses of investigational COVID-19 vaccine

Thu, 08/13/2020 - 12:00
Johnson & Johnson (NYSE: JNJ) (the Company) announced its Janssen Pharmaceutical Companies have entered into an agreement with the U.S. government for the large scale domestic manufacturing and delivery in the U.S. of 100 million doses of Janssen’s SARS-CoV-2 investigational vaccine, Ad26.COV2.S, for use in the United States following approval or Emergency Use Authorization by the U.S. Food and Drug Administration (FDA).

Preliminary study of 300+ COVID-19 patients suggests convalescent plasma therapy effective

Thu, 08/13/2020 - 10:00
A preliminary analysis of an ongoing study of more than 300 COVID-19 patients treated with convalescent plasma therapy at Houston Methodist suggests the treatment is safe and effective. The results, which appear now in The American Journal of Pathology, represents one of the first peer-reviewed publications in the country assessing efficacy of convalescent plasma.

Lilly initiates Phase 3 trial of LY-CoV555 for prevention of COVID-19 at long-term care facilities in partnership with the National Institute of Allergy and Infectious Diseases (NIAID)

Wed, 08/12/2020 - 12:00
Eli Lilly and Company (NYSE: LLY) announced the initiation of BLAZE-2, a Phase 3 trial studying LY-CoV555 for the prevention of SARS-CoV-2 infection and COVID-19 in residents and staff at long-term care facilities in the U.S. (skilled nursing facilities, commonly referred to as nursing homes, and assisted living facilities). LY-CoV555, the lead antibody from Lilly's collaboration with AbCellera, is a neutralizing antibody against SARS-CoV-2, the virus that causes COVID-19.

Scientists identify hundreds of drug candidates to treat COVID-19

Wed, 08/12/2020 - 10:00
Scientists at the University of California, Riverside, have used machine learning to identify hundreds of new potential drugs that could help treat COVID-19, the disease caused by the novel coronavirus, or SARS-CoV-2.

"There is an urgent need to identify effective drugs that treat or prevent COVID-19," said Anandasankar Ray, a professor of molecular, cell, and systems biology who led the research.

Pfizer announces agreement with Gilead to manufacture remdesivir for treatment of COVID-19

Tue, 08/11/2020 - 10:00
Pfizer Inc. (NYSE: PFE) announced a multi-year agreement with Gilead Sciences, Inc. to manufacture and supply Gilead's investigational antiviral remdesivir, as one of multiple external manufacturing organizations supporting efforts to scale up supply of the investigational treatment for COVID-19. Under the terms of the agreement, Pfizer will provide contract manufacturing services at Pfizer's McPherson, Kansas facility to manufacture and supply remdesivir for Gilead.

What the rest of the world can learn from South Korea's COVID-19 response

Mon, 08/10/2020 - 10:00
As the world continues to closely monitor the newest coronavirus outbreak, the government of South Korea has been able to keep the disease under control without paralyzing the national health and economic systems. In a new research article published in The American Review of Public Administration, University of Colorado Denver researcher Jongeun You reviewed South Korea's public health policy to learn how the country managed coronavirus from January through April 2020.

Sanofi and GSK selected for Operation Warp Speed to supply United States government with 100 million doses of COVID-19 vaccine

Fri, 08/07/2020 - 10:00
Sanofi and GSK announced a collaborative effort with the U.S. government to accelerate the development and manufacturing of a COVID-19 recombinant protein-based vaccine.

The vaccine candidate, developed by Sanofi in partnership with GSK, is based on the recombinant protein-based technology used by Sanofi to produce an influenza vaccine, and GSK's established pandemic adjuvant technology.